December 14, 2019
Validation of alpha1-NaKA inhibition as a novel therapeutic strategy for the mouse model of Angelman syndrome
$200,000 (2 years) At approximately two weeks of age in a proven AS mouse model, there is an increase in the expression and subsequent activity of a specific molecule prior to other molecules in the AS brain, which results in […]
Read more